SCHEMBL3203668

SCHEMBL3203668

Cc1ccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)cc1NS(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 7/20 0.36
PDE4D Q08499 3/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
ADRB2 P07550 2/20 0.33
ADRB1 P08588 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
BACE1 P56817 1/20 0.31
CYP17A1 P05093 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
RAB9A P51151 1/20 0.31
PTGS1 P23219 3/20 0.31
PTGS2 P35354 3/20 0.31
CCNT1 O60563 1/20 0.30
CDK9 P50750 1/20 0.30
ACLY P53396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193120 0.86 ACLY (0.33) PDE4BHRH4ACLY
SCHEMBL3210253 0.85 NR3C1 (0.41) ADRB3PDE4DPDE4APDE4BPDE4C
SCHEMBL3204654 0.83 HRH4 (0.33) PDE4DPDE4APDE4BPDE4CHRH4
SCHEMBL3205112 0.82 HRH4 (0.38) HRH4
SCHEMBL3212622 0.80 PDE4A (0.33) PDE4AHRH4ACLY
SCHEMBL3207210 0.80 TAAR1 (0.43) PDE4DPDE4APDE4BPDE4CHRH4
SCHEMBL3194668 0.80 RORC (0.35) HRH4ACLY
SCHEMBL3214943 0.79 HRH4 (0.33) HRH4ACLY
SCHEMBL3202779 0.79 LMNA (0.38) HRH4KDM4EALDH1A1ACLY
SCHEMBL3202234 0.79 ADRA2A (0.36) HRH4CYP17A1NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B ADRB3 58/4885PDE4D 9/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.